Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G1 arrest induction

Cancer Science

Volumn 101, Issue 4, 2010, Pages 913-919

  Horie, Kazutaka ^a   Tsuchihara, Masami ^a   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN; PROTEIN P21; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; GENETICS; MELANOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; G1 PHASE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEONECTIN; RNA, SMALL INTERFERING; SKIN NEOPLASMS;

EID: 77957274271     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01476.x     Document Type: Article

References (34)

1. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049-54.
2. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47: 1495-506.
3. Hasselaar P, Sage EH. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 1992; 49: 272-83.
4. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 1992; 89: 1281-5.
5. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998; 273: 29635-40.
6. Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993; 121: 1433-44.
7. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995; 43: 791-800.
8. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004; 92: 679-90.
9. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008; 27: 691-705.
10. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108: 210-4.
11. Barth PJ, Moll R, Ramaswamy A. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch 2005; 446: 532-6.
12. Koukourakis MI, Giatromanolaki A, Brekken RA et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003; 63: 5376-80.
13. Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003; 97: 2412-9.
14. Guweidhi A, Kleeff J, Adwan H et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005; 242: 224-34.
15. Yamanaka M, Kanda K, Li NC et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166: 2495-9.
16. Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25: 319-25.
17. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30: 339-44.
18. Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res 2000; 60: 6868-74.
19. Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008; 12: 637-45.
20. Shi Q, Bao S, Song L et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 2007; 26: 4084-94.
21. Ledda MF, Adris S, Bravo AI et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3: 171-6.
22. Alvarez MJ, Prada F, Salvatierra E et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 2005; 65: 5123-32.
23. Prada F, Benedetti LG, Bravo AI, Alvarez MJ, Carbone C, Podhajcer OL. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol 2007; 127: 2618-28.
24. Ikuta Y, Nakatsura T, Kageshita T et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11: 8079-88.
25. Ikuta Y, Hayashida Y, Hirata S et al. Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci 2009; 100: 132-7.
26. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
27. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
28. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999; 18: 7637-43.
29. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20: 3224-33.
30. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008; 283: 22826-37.
31. Martinek N, Shahab J, Sodek J, Ringuette M. Is SPARC an evolutionarily conserved collagen chaperone? J Dent Res 2007; 86: 296-305.
32. Yiu GK, Chan WY, Ng SW et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159: 609-22.
33. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007; 5: 1015-30.
34. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 2007; 170: 1054-63.